Mostrar el registro sencillo del ítem

Effects of palmitoylethanolamide (PEA) on nociceptive, musculoskeletal and neuropathic pain: systematic review and meta-analysis of clinical evidence

dc.creatorScuteri, Damianaes_ES
dc.creatorGuida, Francescaes_ES
dc.creatorBoccella, Serenaes_ES
dc.creatorPalazzo, Enzaes_ES
dc.creatorMaione, Sabatinoes_ES
dc.creatorRodríguez-Landa, Juan Franciscoes_ES
dc.creatorMartínez-Mota, Luciaes_ES
dc.creatorTonin, Paoloes_ES
dc.creatorBagetta, Giacintoes_ES
dc.creatorTiziana Corasaniti, Mariaes_ES
dc.date2022
dc.date.accessioned2024-12-09T18:17:19Z
dc.date.available2024-12-09T18:17:19Z
dc.date.issued2022
dc.identifierJC06NC22es_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/8144
dc.identifier.urihttps://doi.org/10.3390/pharmaceutics14081672
dc.descriptionSome 30−50% of the global population and almost 20% of the European population actually suffer from chronic pain, which presents a tremendous burden to society when this pain turns into a disability and hospitalization. Palmitoylethanolamide (PEA) has been demonstrated to improve pain in preclinical contexts, but an appraisal of clinical evidence is still lacking. The present study aimed at addressing the working hypothesis for the efficacy of PEA for nociceptive musculoskeletal and neuropathic pain in the clinical setting. The systematic search, selection and analysis were performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 recommendations. The primary outcome was pain reduction, as measured by a pain assessment scale. The secondary outcome was improvement in quality of life and/or of parameters of function. The results obtained for a total of 933 patients demonstrate the efficacy of PEA over the control (p < 0.00001), in particular in six studies apart from the two randomized, double-blind clinical trials included. However, the results are downgraded due to the high heterogeneity of the studies (I2 = 99%), and the funnel plot suggests publication bias. Efficacy in achieving a reduction in the need for rescue medications and improvement in functioning, neuropathic symptoms and quality of life are reported. Therefore, adequately powered randomized, double-blind clinical trials are needed to deepen the domains of efficacy of add-on therapy with PEA for chronic pain. PROSPERO registration: CRD42022314395.es_ES
dc.formatPDFes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation14(8):1672
dc.rightsAcceso Cerradoes_ES
dc.titleEffects of palmitoylethanolamide (PEA) on nociceptive, musculoskeletal and neuropathic pain: systematic review and meta-analysis of clinical evidencees_ES
dc.typeArtículoes_ES
dc.contributor.affiliationPharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy
dc.contributor.emaildamiana.scuteri@unical.it (D.S.); giacinto.bagetta@unical.it (G.B.)
dc.relation.jnabreviadoPHARMACEUTICS
dc.relation.journalPharmaceutics
dc.identifier.placeSuiza
dc.date.published2022
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñiz
dc.identifier.eissn1999-4923
dc.identifier.doi10.3390/pharmaceutics14081672
dc.subject.kwPalmitoylethanolamide
dc.subject.kwPEA
dc.subject.kwNociceptive pain
dc.subject.kwNeuropathic pain
dc.subject.kwClinical setting


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem